Risks of proton-pump inhibitors: What every doctor should know

Medical Journal of Australia

Volumn 190, Issue 3, 2009, Pages 109-110

  Talley, Nicholas J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CALCIUM; CYANOCOBALAMIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MAGNESIUM; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BACTERIAL INFECTION; CALCIUM ABSORPTION; CALCIUM BLOOD LEVEL; CLOSTRIDIUM DIFFICILE; COMMUNITY ACQUIRED PNEUMONIA; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; INFECTION RISK; INTERSTITIAL NEPHRITIS; INTESTINE FLORA; INTESTINE INFECTION; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MALABSORPTION; MEDICAL PRACTICE; PHARMACEUTICAL CARE; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STOMACH ACID; STOMACH CANCER; STOMACH DISEASE;

EID: 61349172528     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb02305.x     Document Type: Editorial

References (16)

1. Roughead EE, Ramsay EN, Pratt NL, et al. Proton-pump inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust 2009; 190: 114-116.
2. Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet 2006; 367: 2086-2100.
3. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292: 1955-1960.
4. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-955.
5. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-2995.
6. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056.
7. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture JAMA 2006; 296: 2947-2953.
8. Targownik LE, Lix LM, Metge CJ, et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008; 179: 319-326.
9. Talley NJ, Jung HK, Jiang X, Locke GR. Is there an increased risk of hip fracture in patients on long-term PPI therapy? Nat Clin Pract Gastroenterol Hepatol 2007; 4: 420-421.
10. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006; 355: 1834-1836.
11. 12). Ann Intern Med 1994; 120: 211-215.
12. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-1022.
13. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 661-669.
14. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Concensus Report. Gut 2007; 56: 772-781.
15. Yang YX, Hennessy S, Propert K, et al. Chronic proton pump inhibitor therapy and the risk of colorectal cancer Gastroenterology 2007; 133: 748-754.
16. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007; 68: 65-72.